Patient Goals and Concomitant Needs Help Guide TKI Selection in CML - a conversation with Dr. Jorge Cortes
https://www.onclive.com/view/patient-goals-and-concomitant-needs-help-gu...
Jorge Cortes, MD, discusses available TKIs and how to navigate optimal treatment selection for patients with chronic myeloid leukemia.
"What are the next steps for TKI and CML research?
One of the areas where CML is still deficient is in treatment discontinuation. We've made tremendous progress since we started using TKIs. We were happy with the progress, but we just assumed that the patients will be taking them for the rest of their lives. When we realized that there was a subset of patients who could stop therapy, that became fantastic, but the reality is that today is only roughly 25% to 30% of all patients [with CML] can successfully stop therapy. That's good, but it's not even half of patients."
